Advertisement

 

 

Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.
Author Information (click to view)

Slogrove AL, Clayden P, Abrams EJ,


Slogrove AL, Clayden P, Abrams EJ, (click to view)

Slogrove AL, Clayden P, Abrams EJ,

Advertisement

Current opinion in HIV and AIDS 2017 04 19() doi 10.1097/COH.0000000000000386

Abstract
PURPOSE OF REVIEW
As optimized antiretroviral therapy (ART) regimens are prepared for introduction in low-income and middle-income countries (LMIC), we consider the current evidence related to dosing, efficacy and safety during pregnancy and breastfeeding of next-generation first-line and second-line ART regimens proposed for imminent introduction in the global marketplace.

RECENT FINDINGS
Pregnancy pharmacokinetic considerations include potentially insufficient efavirenz exposure if dosed at 400 mg/day, the need for twice daily darunavir dosing and the paucity of data related to tenofovir alafenamide and dolutegravir dosing, safety and efficacy. Increasingly evidence suggests an association with adverse birth outcomes, particularly in women conceiving on ART, and with varying risk by drug and drug combination. Clinical trials and studies are in progress or planned that aim to determine dosing, safety and efficacy of several new antiretrovirals (ARVs).

SUMMARY
Having a universal, highly potent and safe ART regimen for all individuals living with HIV in LMIC including pregnant women is clearly the most beneficial strategy to keep mothers alive and healthy and to prevent transmission of HIV to their children. It will have to be determined whether the use of this next generation of optimized ARVs will also optimize health outcomes of pregnant women and their children.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 + nineteen =

[ HIDE/SHOW ]